期刊
CANCER DISCOVERY
卷 13, 期 1, 页码 19-22出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-22-1199
关键词
-
类别
Hattori and colleagues developed drug-peptide conjugates using targeted small-molecule covalent inhibitors to generate cancer neoantigens, inducing an immune response against oncogene-mutant cancer cells. This immunotherapy strategy shows potential in overcoming treatment-induced resistance commonly observed in small molecule-based targeted anticancer drugs.
In this issue, Hattori and colleagues capitalized on targeted small-molecule covalent inhibitors of one KRAS mutant with a G12C substitution and of other oncoproteins to create drug-peptide conjugates that serve as cancer neoantigens that prompt an immune response to oncogene-mutant cancer cells. This immunotherapy strategy can serve as an effective approach to overcome the treatment-induced resistance that limits the effectiveness of essentially all small molecule-based targeted anticancer drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据